RU2016151235A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016151235A3 RU2016151235A3 RU2016151235A RU2016151235A RU2016151235A3 RU 2016151235 A3 RU2016151235 A3 RU 2016151235A3 RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A3 RU2016151235 A3 RU 2016151235A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170140.9 | 2014-05-28 | ||
| EP14170140 | 2014-05-28 | ||
| EP14180572.1 | 2014-08-11 | ||
| EP14180572 | 2014-08-11 | ||
| PCT/EP2015/061457 WO2015181098A1 (en) | 2014-05-28 | 2015-05-22 | Antibodies binding to human and cynomolgus cd3 epsilon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016151235A RU2016151235A (ru) | 2018-06-28 |
| RU2016151235A3 true RU2016151235A3 (enExample) | 2019-01-18 |
Family
ID=53268799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016151235A RU2016151235A (ru) | 2014-05-28 | 2015-05-22 | Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170233475A1 (enExample) |
| EP (2) | EP3763739A1 (enExample) |
| JP (1) | JP6738285B2 (enExample) |
| KR (1) | KR20170003591A (enExample) |
| CN (1) | CN106459201A (enExample) |
| AU (1) | AU2015266077A1 (enExample) |
| BR (1) | BR112016022819A2 (enExample) |
| CA (1) | CA2942453A1 (enExample) |
| IL (1) | IL247740A0 (enExample) |
| MX (1) | MX2016015389A (enExample) |
| RU (1) | RU2016151235A (enExample) |
| SG (1) | SG11201609950YA (enExample) |
| WO (1) | WO2015181098A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| WO2017150762A1 (ko) * | 2016-02-29 | 2017-09-08 | (주)메디톡스 | 항-CD3γε 항체 및 이의 용도 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| CN118126180A (zh) * | 2016-12-22 | 2024-06-04 | 第一三共株式会社 | 抗cd3抗体和包含所述抗体的分子 |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| JP2020521791A (ja) | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体 |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| US11319371B2 (en) | 2017-06-05 | 2022-05-03 | Numab Therapeutics AG | Anti-CD3 antibodies |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 |
| US12486325B2 (en) | 2017-09-21 | 2025-12-02 | WuXi Biologics Ireland Limited | Anti-CD3epsilon antibodies |
| CN111108119B (zh) * | 2017-09-21 | 2022-11-15 | 上海药明生物技术有限公司 | 新型抗CD3ε抗体 |
| EP3717632B1 (en) | 2017-11-30 | 2022-10-26 | F. Hoffmann-La Roche AG | B-cell cultivation method |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| TW202016144A (zh) * | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
| CN115916818A (zh) | 2019-12-11 | 2023-04-04 | 库利南肿瘤股份有限公司 | 抗cd19抗体和多特异性结合蛋白 |
| PE20230389A1 (es) * | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| JP7851303B2 (ja) * | 2020-09-24 | 2026-04-24 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒトｃｄ３イプシロンに結合する新規なヒト抗体 |
| CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CN115536740A (zh) * | 2021-06-30 | 2022-12-30 | 苏州方德门达新药开发有限公司 | 介导细胞内有效滞留cd3的空间构象表位及其应用 |
| CN113755435B (zh) * | 2021-10-15 | 2023-10-13 | 苏州药明康德新药开发有限公司 | 一种食蟹猴pbmc分离方法 |
| WO2023183766A1 (en) * | 2022-03-20 | 2023-09-28 | Abcellera Biologics Inc. | Anti-cd3 antibodies and t-cell engagers and methods of use |
| JP2025513714A (ja) * | 2022-03-22 | 2025-04-30 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｃｄ３に特異的な脱免疫抗体 |
| US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD272473B3 (de) * | 1988-06-13 | 1993-01-21 | Univ Leipzig | Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten |
| JPH0630786A (ja) * | 1992-07-14 | 1994-02-08 | Kyowa Hakko Kogyo Co Ltd | バイスペシフィック抗体 |
| SG188175A1 (en) * | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| US8236308B2 (en) * | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| SI2155788T1 (sl) * | 2007-04-03 | 2012-11-30 | Amgen Res Munich Gmbh | Bispecifični vezavni element specifičen za križane vrste |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| WO2012162067A2 (en) * | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| US20170073415A1 (en) * | 2014-05-12 | 2017-03-16 | Numab Ag | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
-
2015
- 2015-05-22 CN CN201580026998.5A patent/CN106459201A/zh active Pending
- 2015-05-22 AU AU2015266077A patent/AU2015266077A1/en not_active Abandoned
- 2015-05-22 MX MX2016015389A patent/MX2016015389A/es unknown
- 2015-05-22 SG SG11201609950YA patent/SG11201609950YA/en unknown
- 2015-05-22 KR KR1020167033022A patent/KR20170003591A/ko not_active Withdrawn
- 2015-05-22 EP EP20163877.2A patent/EP3763739A1/en not_active Withdrawn
- 2015-05-22 BR BR112016022819A patent/BR112016022819A2/pt not_active Application Discontinuation
- 2015-05-22 JP JP2016569639A patent/JP6738285B2/ja not_active Expired - Fee Related
- 2015-05-22 WO PCT/EP2015/061457 patent/WO2015181098A1/en not_active Ceased
- 2015-05-22 RU RU2016151235A patent/RU2016151235A/ru not_active Application Discontinuation
- 2015-05-22 CA CA2942453A patent/CA2942453A1/en not_active Abandoned
- 2015-05-22 EP EP15725002.8A patent/EP3149041A1/en not_active Ceased
-
2016
- 2016-09-11 IL IL247740A patent/IL247740A0/en unknown
- 2016-11-22 US US15/359,199 patent/US20170233475A1/en not_active Abandoned
-
2020
- 2020-01-23 US US16/751,046 patent/US20200325224A1/en not_active Abandoned
- 2020-01-23 US US16/751,062 patent/US20200299385A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200325224A1 (en) | 2020-10-15 |
| BR112016022819A2 (pt) | 2018-01-16 |
| MX2016015389A (es) | 2017-04-13 |
| US20200299385A1 (en) | 2020-09-24 |
| EP3149041A1 (en) | 2017-04-05 |
| RU2016151235A (ru) | 2018-06-28 |
| SG11201609950YA (en) | 2016-12-29 |
| AU2015266077A1 (en) | 2016-09-29 |
| CN106459201A (zh) | 2017-02-22 |
| JP2017516786A (ja) | 2017-06-22 |
| CA2942453A1 (en) | 2015-12-03 |
| IL247740A0 (en) | 2016-11-30 |
| KR20170003591A (ko) | 2017-01-09 |
| WO2015181098A1 (en) | 2015-12-03 |
| JP6738285B2 (ja) | 2020-08-12 |
| US20170233475A1 (en) | 2017-08-17 |
| EP3763739A1 (en) | 2021-01-13 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200806 |